ESMO LBA Insights | The ADC Moment in Gynecologic Oncology: Professor Domenica Lorusso Discusses the TroFuse-005 Study
The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. In the field of gynecologic oncology, one major study that attracted considerable attention was expected to reshape the treatment landscape for advanced endometrial cancer in the later-line setting. The randomized, open-label, global phase III TroFuse-005 study (ENGOT-en23/GOG-3095) demonstrated that the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (Sac-TMT) significantly improved progression-free survival (PFS) and overall survival (OS) compared with treatment of physician's choice (TPC) in patients with previously treated advanced or recurrent endometrial cancer. The objective response rate (ORR) was nearly doubled, making Sac-TMT the first TROP2 ADC in this patient population to demonstrate improvements in both OS and PFS compared with chemotherapy.









